WGU D027 OBJECTIVE ASSESSMENT STUDY GUIDE
2026/2027 | Advanced Pathopharmacological Foundations |
Questions & Verified Answers | Pass Guaranteed - A+ Graded
Section 1: Principles of Pharmacology – PK/PD, ADME, Receptors,
and Adverse Drug Reactions
Q1: A 68-year-old male with atrial fibrillation is started on oral rivaroxaban 20mg daily.
The prescriber explains that this drug has high bioavailability, meaning:
A. It undergoes extensive first-pass metabolism in the liver before reaching systemic
circulation
B. A significant fraction of the administered dose reaches the systemic circulation
unchanged [CORRECT]
C. It is primarily eliminated unchanged through the kidneys without metabolism
D. It requires active transport across the gastrointestinal mucosa for absorption
Correct Answer: B
Rationale: Bioavailability refers to the proportion of an administered drug that reaches
systemic circulation in an unchanged form. High bioavailability indicates extensive
absorption with minimal first-pass loss. Option A describes low bioavailability, option C
describes renal elimination (not bioavailability), and option D describes a specific
absorption mechanism rather than bioavailability percentage.
,Q2: A patient on phenytoin for seizure control has a drug level of 8 mcg/mL (therapeutic
range 10-20 mcg/mL) despite compliant dosing. The provider increases the dose
slightly, and the level jumps to 22 mcg/mL. This pattern suggests:
A. Zero-order kinetics at lower doses transitioning to first-order at higher doses
B. First-order kinetics throughout the therapeutic range
C. Zero-order kinetics once metabolic enzymes become saturated [CORRECT]
D. Capacity-limited protein binding causing increased free drug
Correct Answer: C
Rationale: Phenytoin exhibits Michaelis-Menten (capacity-limited) kinetics. At low
concentrations, metabolism follows first-order kinetics, but as CYP2C9/2C19 enzymes
saturate, zero-order kinetics predominate—small dose increases produce
disproportionate level increases. Option A reverses the concept, option B ignores
saturation, and option D describes protein binding issues rather than metabolic kinetics.
Q3: A 45-year-old female with anxiety is prescribed buspirone. The pharmacist counsels
that grapefruit juice should be avoided because it:
A. Inhibits CYP3A4, increasing buspirone levels and side effects [CORRECT]
B. Induces CYP2D6, reducing buspirone efficacy
C. Alters P-glycoprotein, decreasing buspirone absorption
D. Competes for albumin binding, increasing free drug concentration
Correct Answer: A
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4, increasing bioavailability of CYP3A4 substrates like buspirone. Option B
,incorrectly identifies CYP2D6 induction, option C describes P-gp effects (not relevant
here), and option D describes protein binding displacement (not grapefruit's
mechanism).
Q4: A patient on warfarin (INR 2.5, therapeutic) starts TMP-SMX for a UTI. Five days
later, INR is 4.2. This interaction occurs primarily through:
A. TMP-SMX inhibits CYP2C9, reducing S-warfarin metabolism [CORRECT]
B. Sulfamethoxazole induces vitamin K synthesis in gut bacteria
C. Trimethoprim displaces warfarin from albumin binding sites
D. Both drugs compete for renal tubular secretion
Correct Answer: A
Rationale: TMP-SMX inhibits CYP2C9, the primary enzyme metabolizing S-warfarin (the
more potent enantiomer). This reduces clearance and increases INR. Option B is
incorrect (antibiotics reduce vitamin K synthesis, potentially increasing INR, but this isn't
the primary mechanism here). Option C describes protein binding displacement
(minimal contribution to INR changes). Option D describes renal competition (warfarin
is hepatically metabolized).
Q5: Calculate the volume of distribution (Vd) for a drug when a 70-year-old male (70 kg)
receives an IV bolus of 500 mg, and the measured plasma concentration is 10 mg/L
immediately after distribution:
A. 5 L
B. 50 L [CORRECT]
C. 500 L
, D. 0.05 L
Correct Answer: B
Rationale: Vd = Dose / Plasma Concentration = 500 mg / 10 mg/L = 50 L. This indicates
extensive tissue distribution beyond plasma volume (approximately 3 L). Option A
would suggest minimal distribution, option C suggests extreme sequestration (like
digoxin), and option D represents a calculation error.
Q6: A patient with chronic pain is switched from codeine to morphine due to inadequate
pain control. Genetic testing reveals the patient is a CYP2D6 poor metabolizer. This
means:
A. Codeine was not converted to its active metabolite morphine effectively [CORRECT]
B. The patient will metabolize morphine more rapidly than normal
C. Morphine will have decreased efficacy due to CYP2D6 deficiency
D. The patient requires higher morphine doses due to ultra-rapid metabolism
Correct Answer: A
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine
(the active analgesic). Poor metabolizers cannot effectively convert codeine, resulting in
inadequate pain relief. Option B is incorrect (morphine doesn't require CYP2D6
activation). Option C is incorrect (morphine works directly). Option D describes
ultra-rapid metabolizers, not poor metabolizers.
2026/2027 | Advanced Pathopharmacological Foundations |
Questions & Verified Answers | Pass Guaranteed - A+ Graded
Section 1: Principles of Pharmacology – PK/PD, ADME, Receptors,
and Adverse Drug Reactions
Q1: A 68-year-old male with atrial fibrillation is started on oral rivaroxaban 20mg daily.
The prescriber explains that this drug has high bioavailability, meaning:
A. It undergoes extensive first-pass metabolism in the liver before reaching systemic
circulation
B. A significant fraction of the administered dose reaches the systemic circulation
unchanged [CORRECT]
C. It is primarily eliminated unchanged through the kidneys without metabolism
D. It requires active transport across the gastrointestinal mucosa for absorption
Correct Answer: B
Rationale: Bioavailability refers to the proportion of an administered drug that reaches
systemic circulation in an unchanged form. High bioavailability indicates extensive
absorption with minimal first-pass loss. Option A describes low bioavailability, option C
describes renal elimination (not bioavailability), and option D describes a specific
absorption mechanism rather than bioavailability percentage.
,Q2: A patient on phenytoin for seizure control has a drug level of 8 mcg/mL (therapeutic
range 10-20 mcg/mL) despite compliant dosing. The provider increases the dose
slightly, and the level jumps to 22 mcg/mL. This pattern suggests:
A. Zero-order kinetics at lower doses transitioning to first-order at higher doses
B. First-order kinetics throughout the therapeutic range
C. Zero-order kinetics once metabolic enzymes become saturated [CORRECT]
D. Capacity-limited protein binding causing increased free drug
Correct Answer: C
Rationale: Phenytoin exhibits Michaelis-Menten (capacity-limited) kinetics. At low
concentrations, metabolism follows first-order kinetics, but as CYP2C9/2C19 enzymes
saturate, zero-order kinetics predominate—small dose increases produce
disproportionate level increases. Option A reverses the concept, option B ignores
saturation, and option D describes protein binding issues rather than metabolic kinetics.
Q3: A 45-year-old female with anxiety is prescribed buspirone. The pharmacist counsels
that grapefruit juice should be avoided because it:
A. Inhibits CYP3A4, increasing buspirone levels and side effects [CORRECT]
B. Induces CYP2D6, reducing buspirone efficacy
C. Alters P-glycoprotein, decreasing buspirone absorption
D. Competes for albumin binding, increasing free drug concentration
Correct Answer: A
Rationale: Grapefruit juice contains furanocoumarins that irreversibly inhibit intestinal
CYP3A4, increasing bioavailability of CYP3A4 substrates like buspirone. Option B
,incorrectly identifies CYP2D6 induction, option C describes P-gp effects (not relevant
here), and option D describes protein binding displacement (not grapefruit's
mechanism).
Q4: A patient on warfarin (INR 2.5, therapeutic) starts TMP-SMX for a UTI. Five days
later, INR is 4.2. This interaction occurs primarily through:
A. TMP-SMX inhibits CYP2C9, reducing S-warfarin metabolism [CORRECT]
B. Sulfamethoxazole induces vitamin K synthesis in gut bacteria
C. Trimethoprim displaces warfarin from albumin binding sites
D. Both drugs compete for renal tubular secretion
Correct Answer: A
Rationale: TMP-SMX inhibits CYP2C9, the primary enzyme metabolizing S-warfarin (the
more potent enantiomer). This reduces clearance and increases INR. Option B is
incorrect (antibiotics reduce vitamin K synthesis, potentially increasing INR, but this isn't
the primary mechanism here). Option C describes protein binding displacement
(minimal contribution to INR changes). Option D describes renal competition (warfarin
is hepatically metabolized).
Q5: Calculate the volume of distribution (Vd) for a drug when a 70-year-old male (70 kg)
receives an IV bolus of 500 mg, and the measured plasma concentration is 10 mg/L
immediately after distribution:
A. 5 L
B. 50 L [CORRECT]
C. 500 L
, D. 0.05 L
Correct Answer: B
Rationale: Vd = Dose / Plasma Concentration = 500 mg / 10 mg/L = 50 L. This indicates
extensive tissue distribution beyond plasma volume (approximately 3 L). Option A
would suggest minimal distribution, option C suggests extreme sequestration (like
digoxin), and option D represents a calculation error.
Q6: A patient with chronic pain is switched from codeine to morphine due to inadequate
pain control. Genetic testing reveals the patient is a CYP2D6 poor metabolizer. This
means:
A. Codeine was not converted to its active metabolite morphine effectively [CORRECT]
B. The patient will metabolize morphine more rapidly than normal
C. Morphine will have decreased efficacy due to CYP2D6 deficiency
D. The patient requires higher morphine doses due to ultra-rapid metabolism
Correct Answer: A
Rationale: Codeine is a prodrug requiring CYP2D6-mediated conversion to morphine
(the active analgesic). Poor metabolizers cannot effectively convert codeine, resulting in
inadequate pain relief. Option B is incorrect (morphine doesn't require CYP2D6
activation). Option C is incorrect (morphine works directly). Option D describes
ultra-rapid metabolizers, not poor metabolizers.
